Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom. Show more

14/15 Conduit Street, London, W1S 2XJ, United Kingdom

https://www.tizianalifesciences.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

143.8M

52 Wk Range

$1.08 - $2.60

Previous Close

$1.13

Open

$1.15

Volume

297,881

Day Range

$1.05 - $1.17

Enterprise Value

139.6M

Cash

4.01M

Avg Qtr Burn

N/A

Insider Ownership

43.48%

Institutional Own.

2.94%

Qtr Updated

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Intranasal Foralumab Details Alzheimer's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab Details COVID-19	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milciclib (pan-CDK inhibitor) Details Hepatocellular carcinoma, Solid tumor/s	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Multiple System Atrophy	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab (anti-CD3 mAb) Details Crohns disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Neurodegenerative disease, Amyotrophic lateral sclerosis	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.